Claims
- 1. A tricyclic compound represented by formula (I): ##STR233## wherein is
- (a) single bond, or
- (b) double bond;
- X.sub.1 -X.sub.2 is:
- (a) --CH.sub.2 --O--,
- (b) --CH.sub.2 --S--,
- (c) --CH.sub.2 --CH.sub.2 --, or
- (d) --CH.dbd.CH--;
- G.sup.A and G.sup.B are independently:
- (a) lower alkyl,
- (b) halogen, or
- (c) OR.sup.1, wherein R.sup.1 is:
- (a)' hydrogen, or
- (b)' lower alkyl;
- g.sup.A and g.sup.B are independently 0, 1, 2 or 3;
- one of R.sup.A and R.sup.B is hydrogen and the other is --Y--COOR.sup.1a, wherein R.sup.1a has the same significance as R.sup.1, and wherein Y is:
- (a)' single bond,
- (b)' --CR.sup.1b R.sup.1c --(CH.sub.2).sub.m --, or
- (c)' --CR.sup.1b .dbd.CR.sup.1c --(CH.sub.2).sub.m --, wherein each of R.sup.1b and R.sup.1c independently has the same significance as R.sup.1 and m is 0, 1, 2, 3 or 4, wherein the left side of the formula in (b)' and (c)' is bound to the mother nucleus;
- W.sup.1 is:
- (a) --S--,
- (b) --SO.sub.2 --,
- (c) --O--,
- (d) --NR.sup.1d, wherein R.sup.1d has the same significance as R.sup.1,
- (e) --NHCO--,
- (f) .dbd.N--,
- (g) .dbd.CH--, or
- (h) --CH.sub.2 --,
- wherein the left side of the formula in (e) through (g) is bound to the mother nucleus;
- n is 0, 1, 2, 3 or 4;
- W.sub.2 is;
- (a) single bond,
- (b) --S--, or
- (c) --NR.sup.1e -- wherein R.sup.1e has the same significance as R.sup.1 ;
- Z is: ##STR234## wherein a is:
- (a)' --CH.sub.2 --,
- (b)' --NH--,
- (c)' --O--,
- (d)' --S--, or
- (e)' --SO.sub.2 --
- b, c, d.sup.1, d.sup.2, d.sup.3 and d.sup.4 are independently:
- (a)' .dbd.CH--, or
- (b)' .dbd.N--, wherein at least one of d.sup.1, d.sup.2, d.sup.3 and d.sup.4 is .dbd.N--;
- Q.sup.1, Q.sup.2 and Q.sup.3 are independently:
- (a)' hydrogen,
- (b)' lower alkyl,
- (c)' benzyl,
- (d)' substituted benzyl wherein each substituent on the phenyl independently represents 1 to 3 of:
- (a)" halogen, or
- (b)" OR.sup.1f wherein R.sup.1f has the same significance as R.sup. 1 ; and a substituent on the methylene is one of:
- (c)" --OR.sup.1g wherein R.sup.1g has the same significance as R.sup.1 ;
- (e)' phenyl,
- (f)' halogen,
- (g)' --CF.sub.3,
- (h)' nitro,
- (i)' --CN,
- (j)' --N.sub.3,
- (k)' --COOR.sup.2,
- (l)' --OR.sup.2,
- (m)' --OCOR.sup.2,
- (n)' --SR.sup.2,
- (o)' --COR.sup.2
- (p)' CONR.sup.2a R.sup.2b, wherein R.sup.2a and R.sup.2b are independently:
- (a)" hydrogen,
- (b)" straight or branched alkyl having 1 to 18 carbon atoms,
- (c)" benzyl, or
- (d)" phenyl,
- (q)' methylenedioxyl formed together with the ortho-position;
- on the saturated methylene carbon atom or (e) and (h) in the definition for Z,
- (r)' .dbd.O,
- (s)' .dbd.S;
- and pharmaceutically acceptable salts thereof.
- 2. A compound according to claim 1, wherein one of R.sup.A and R.sup.B is hydrogen and the other is --Y--COOH.
- 3. A compound according to claim 2, wherein Y is selected from the group consisting single bond, --CH.sub.2 --, ##STR235## --C(CH.sub.3).sub.2 -- and --CH.sub.2 CH.sub.2 --.
- 4. A compound according to claim 3, wherein X.sup.1 -X.sup.2 is --CH.sub.2 --O--; W.sup.1 is .dbd.CH--; n is 1 and W.sup.2 is a single bond.
- 5. A compound according to claim 3, wherein X.sup.1 -X.sup.2 is --CH.sub.2 --O--; W.sup.1 is --S--, --O--, .dbd.N-- or .dbd.CH--; n is 1 or 2; and w.sup.2 is a single bond.
- 6. A compound according to claim 1, wherein said salt is selected from the group consisting of acid addition salt, metal salt, ammonium salt, organic amine addition salt and amino acid addition salt.
- 7. (E)-11-[2-(1H-Imidazo[4,5-b]pyridin-1-yl)ethylidene]-6,11-dihydrodibenz[b,e]oxepin-2-carboxylate.
- 8. (E)-11-[2-(1H-Imidazo[4,5-c]pyridin-1-yl)ethylidene]-6,11-dihydrodibenz[b,e]oxepin-2-carboxylate.
- 9. (E)-11-[2-(1H-Imidazo[4,5-c]pyridin-3-yl)ethylidene]-6,11-dihydrodibenz[b,e]oxepin-2-carboxylate.
- 10. A pharmaceutical composition comprising a pharmaceutical carrier and, as an active ingredient, an effective amount of a tricyclic compound as defined by claim 1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
63-142374 |
Jun 1988 |
JPX |
|
Parent Case Info
This application is a division of application Ser. No. 856,296, filed Mar. 23, 1992, (now U.S. Pat. No. 5,292,931), which is a division of application Ser. No. 612,446, filed Nov. 14, 1990 (now U.S. Pat. No. 5,118,701, issued Jun. 2, 1992), which is a division of application Ser. No. 368,242, filed Jun. 6, 1989 (now U.S. Pat. No. 4,990,363, issued Mar. 12, 1991).
US Referenced Citations (16)
Foreign Referenced Citations (15)
Number |
Date |
Country |
85870 |
Aug 1983 |
EPX |
188802 |
Jul 1986 |
EPX |
214779 |
Mar 1987 |
EPX |
235796 |
Sep 1987 |
EPX |
57-139073 |
Aug 1982 |
JPX |
59-227879 |
Dec 1984 |
JPX |
61-257981 |
Jan 1986 |
JPX |
025798 |
Nov 1986 |
JPX |
152669 |
Nov 1986 |
JPX |
61-152673 |
Nov 1986 |
JPX |
61-152674 |
Nov 1986 |
JPX |
61-152675 |
Nov 1986 |
JPX |
61-152676 |
Nov 1986 |
JPX |
153280 |
Aug 1987 |
JPX |
017877 |
Jan 1988 |
JPX |
Non-Patent Literature Citations (6)
Entry |
Pinder Drugs, 13, 161-167 (1977). |
Tsukada et al., J. Med. Chem., 21 (7) 633-639 (1978). |
Uno et al., J. Med. Chem. 19 (7) 941-976 (1976). |
Bemesovo, Arz. Forsch., 14, 100-105 (1964). |
Melusova, Arz. Forsch., 13, 1039-1045 (1963). |
Alluz, J. Med. Chem., 20 (11) 1499-1501 (1977). |
Divisions (3)
|
Number |
Date |
Country |
Parent |
856296 |
Mar 1992 |
|
Parent |
612446 |
Nov 1990 |
|
Parent |
368242 |
Jun 1989 |
|